Infusion of 5-AZA Pilot Study
Lead Physician: David I. Sandberg, M.D.
Children’s Neuroscience Center has a new brain tumor trial that is open to
qualified participants. The research study is being conducted by David Sandberg, M.D., Professor and
Director of Pediatric Neurosurgery at McGovern Medical School at UTHealth and
Children’s Memorial Hermann Hospital.
study is called “Infusion of 5-Azacytidine (5-AZA) into the Fourth Ventricle or
Resection Cavity in Children with Recurrent Posterior Fossa Ependymoma: A Pilot
Study.” It is open to patients who are age 1 to 21 years old with recurrent
ependymoma that originated in the posterior fossa of the brain.
study employs a novel means of treating ependymoma brain tumors that originate
from the fourth ventricle: infusion of a chemotherapy agent directly into the
fourth ventricle rather than systemic intravenous delivery. The agent being
infused, 5-AZA, has never been infused into the brain in humans but has been
shown to effectively kill ependymoma cells in the laboratory. There will be no
simultaneous systemic chemotherapy.
study is listed at ClinicalTrials.gov, NCT #
02940483, under “Brain Tumor Recurrent.” If you would like
additional information about this study, please contact Bangning Yu, M.D.,
Ph.D., by email at Bangning.Yu@uth.tmc.edu or
call (713) 500-7363.
For more information: ClinicalTrials.gov, NCT # 02940483